Iomai Corporation, a developer of vaccines and immunostimulants delivered to the skin, priced 5.0 million shares at $7 Wednesday. UBS Investment Bank and SG Cowen were the joint book runners on the deal. The stock now trades on the NASDAQ under the symbol "IOMI" and closed at $6.88 today, down -2%.
